Eli Lilly obtains FDA approval for the use of a COVID-19 antibody treatment

The Food and Drug Administration (FDA) granted the first emergency use authorization for an antibody treatment for COVID-19 from pharmacist Eli Lilly.

The investigational neutralizing antibody bamlanivimab (LY-CoV555) 700 mg, which is licensed for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years of age and older with a positive COVID-19 test and may complicate their situation.

According to a pharmacist’s statement, bamlanivimab should be administered as soon as possible after a positive COVID-19 test and within ten days of symptoms onset.

“This emergency authorization allows us to make bamlanivimab available as a COVID-19 treatment for newly diagnosed high-risk patients, adding a valuable tool for physicians struggling with the now growing burden of this global pandemic,” David A. Ricks, Lilly president, and CEO said in the statement.

The Yucatan Times
Newsroom



Comments

comments

more recommended stories

doctoranytime BUSQUE A UN MÉDICO